A Phase 3 interventional study of ezetimibe (plus simvastatin) and placebo (plus simvastatin) in Atherosclerosis, Hypercholesterolemia and Hyperlipoproteinemia Type II, sponsored by Organon and Co. Completed. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-15.
Sponsored by Organon and Co · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing ezetimibe in Atherosclerosis — 2 open to participants now, 2 under way, none of them phase 3. Ezetimibe · Atherosclerosis.
Among the 22 studies testing ezetimibe in Atherosclerosis, this one is the 3rd largest by enrollment, is the only one that started in 2002, is one of 6 in phase 3, and was the 7th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →2 of the 22 studies testing ezetimibe in Atherosclerosis are open now, in 2 countries. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 55+
Universidade do Porto · Sites in Portugal
Ages 18–75
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 30 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 720 is above the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 121 across the 22 interventional studies. Of the 19 that completed or were terminated, 6 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
14 studies in Atherosclerosis by Organon & Co.: none open now, none under way, none of them phase 3. Of 14 finished, 2 (14%) have results posted.
Among the 14 studies in Atherosclerosis by Organon & Co., this one has the largest enrollment of the 13 interventional ones that give a count, is the only one that started in 2002, is one of 4 in phase 3, and was the 2nd registered.
Organon & Co.’s Atherosclerosis studies by the year they started, since 2002.
1 of the studies testing ezetimibe in Atherosclerosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07839741Universidade do PortoLDL Cholesterol Reduction Following Ezetimibe Initiation | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies testing ezetimibe in Atherosclerosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 14 in Atherosclerosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine whether ezetimibe plus simvastatin will be more effective than simvastatin alone in preventing progression of atherosclerosis of the inner layer of the carotid artery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Genotype-confirmed heterozygous familial hypercholesterolemia with written documentation of the genetic diagnosis at the time of screening and LDL-C >=210 mg/dL (5.43 mmol/L), or clinical diagnosis of heterozygous familial hypercholesterolemia, defined as LDL-C >=210 mg/dL (5.43 mmol/L) and at least one of the following:
Exclusion Criteria:
Drug: ezetimibe (plus simvastatin)
Drug: placebo (plus simvastatin)
Drug page: Ezetimibe
oral tablets; ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
Also known as: ZETIA, VYTORIN, SCH 58235, SCH 465981
tablets; placebo to match ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
Change in ultrasound-determined average carotid artery intima-media thickness (IMT) on a per subject basis between baseline and endpoint.
Time frame: 24 months
Proportion of subjects with a reduction in ultrasound-determined average carotid artery IMT between baseline and endpoint.
Time frame: 24 months
Change in ultrasound-determined maximum carotid artery IMT on a per subject basis between baseline and endpoint.
Time frame: 24 months
Proportion of subjects developing new carotid artery plaques between baseline and endpoint.
Time frame: 24 months
Change in ultrasound-determined average carotid artery plus average common femoral artery IMT on a per subject basis between baseline and endpoint.
Time frame: 24 months
No study locations are listed for this record.
Ran from Jun 2002 to primary completion in Apr 2006, 46 months.
Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's 46 months is above that.
Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ezetimibe